DUBLIN, September 16, 2022 /PRNewswire/ — The “Monoclonal Antibodies for Oncology: World Markets” report has been added to from ResearchAndMarkets.com provide.
The present report gives an in depth exposition of the worldwide Monoclonal Antibodies for Oncology Market.
This report highlights the present and future potential of the Monoclonal Antibodies for Oncology Remedy market and features a detailed evaluation of market drivers, challenges, and alternatives.
The report additionally covers market projections until 2027 and market share of main market gamers. The report particulars the Monoclonal Antibodies for Oncology market share based mostly on sort and software.
The report consists of firm profiles of key gamers with detailed info on their industries, financials, product portfolios, and up to date developments. The report additionally gives the influence of the COVID-19 pandemic on this market.
Firm profiles of key gamers together with AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc, Pfizer Inc.
The report consists of
- 25 knowledge tables and 24 further tables
- A Transient Basic Overview of the World Oncology Monoclonal Antibodies Market
- World market development analyses, with market income (gross sales knowledge) for 2020 and 2021, estimates for 2022, and compound annual progress fee (CAGR) projections to 2027
- Highlights of the present and future Monoclonal Antibodies for Oncology Remedy market potential and areas of curiosity to forecast this market throughout varied segments and sub-segments
- Evaluation of the particular market measurement of monoclonal antibodies in oncology remedy, forecast progress tendencies and corresponding market share evaluation by antibody sort, software space and area
- Technological evaluation of key drivers, restraints and alternatives that can form the market over the subsequent 5 years (2022 to 2027)
- In-depth info on rising funding in R&D actions, key technological points, industry-specific challenges, main kinds of end-user markets, and implications of COVID-19 on the progress of this market
- Evaluate of the patent panorama and new developments of the monoclonal antibodies for oncology market and associated scientific trials
- Identification of key stakeholders and evaluation of the aggressive panorama based mostly on latest developments and {industry} income
Most important matters coated:
Chapter 1 Introduction
- Goals and goals of the examine
- Causes for doing this examine
- Report scope
- Sources of data
- Methodology
- Geographical distribution
- Analyst titles
- Personalised search
- Associated Analysis Stories
Chapter 2 Abstract and Highlights
Chapter 3 Market and Know-how Background
- Monoclonal antibodies
- Historical past of monoclonal antibodies
- Benefits and downsides of monoclonal antibodies
- Monoclonal antibodies in oncology
- Forms of monoclonal antibodies
Chapter 4 Market Dynamics
- Market components
- Improve in most cancers incidence
- New product launches
- Improve in well being expenditure and public funding
- License and collaboration agreements
- Market Obstacles
- Worth management
- Regulatory approval pressures
- Entry of biosimilars
- Alternatives
- Affect of Covid-19
Chapter 5 Market Breakdown by Kind
- Forms of monoclonal antibodies for oncology
- Market overview
- Market earnings
- World Oncology Monoclonal Antibody Market By Kind
- Humanized monoclonal antibodies
- Human monoclonal antibodies
- Chimeric monoclonal antibodies
Chapter 6 Market Break up by Utility
- Perception
- Lung most cancers
- Breast most cancers
- Colorectal most cancers
- Leukemia
Chapter 7 Market Breakdown by Area
- Introduction
- North America
- WE
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Remainder of Europe
- Asia Pacific
- China
- India
- Japan
- Remainder of Asia Pacific
- Remainder of the world
- Market measurement and forecast
Chapter 8 Regulatory Elements
- New Monoclonal Antibody Approvals for Oncology
- Recollects, withdrawals and safety alerts
Chapter 9 Patent Examination/New Developments
- New developments
- Section I scientific trials
- Section II scientific trials
- Section III scientific trials
Chapter 10 Aggressive Panorama
- Mergers, acquisitions and collaborations
- Firm market share
Chapter 11 Enterprise Profiles
- Amgen Inc.
- Astrazeneca Prescribed drugs
- Bristol-Myers Squibb
- Eli Lily
- F. Hoffmann-La Roche AG
- GlaxoSmithKline
- Gilead Sciences Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- Merck Kgaa
- Pfizer Inc.
- Sanofi SA
- seagen
For extra info on this report, go to https://www.researchandmarkets.com/r/9v5j5d
Media Contact:
Analysis and Markets
Laura Woodensenior
[email protected]
For EST workplace hours, name +1-917-300-0470
For USA/CAN name toll free +1-800-526-8630
For GMT workplace hours name +353-1-416-8900
US Fax: 646-607-1907
Fax (exterior the US): +353-1-481-1716
Brand: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Analysis and Markets
